Atopic Dermatitis Market Expected to Reach $22.6 Billion by 2031

The atopic dermatitis market size was valued at $5.3 billion in 2021, and is estimated to reach $22.6 billion by 2031, growing at a CAGR of 15.1% from 2022 to 2031. Atopic dermatitis is a condition that makes the person's skin red and itchy. It's common in children but can occur at any age. Atopic dermatitis is long lasting (chronic) and tends to flare periodically. It may be accompanied by asthma or hay fever. No cure has been found for atopic dermatitis. But treatments and self-care measures can relieve itching and prevent new outbreaks.

𝐋𝐢𝐬𝐭 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 :
The report provides a comprehensive analysis of the key players that operate in the global atopic dermatitis market. The key companies profiled in the report include AbbVie Inc., Arcutis Biotherapeutics, Inc., Asana Biosciences, Inc., Astellas Pharma, Inc., Bayer AG, Inc., Bristol-Myers Squibb Inc., Dermavant Sciences, Inc., Eli Lilly and Company, Inc., Galderma, Inc., Incyte Corporation, Inc., Leo Pharma, Inc., Novartis AG, Otsuka Pharmaceuticals Co., Ltd., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi SA, Inc., and Viatris, Inc.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-sample/3353

Rise in initiatives from various governments in improving the infrastructure of hospitals and clinics with the latest equipment, and advancement in atopic dermatitis industry are expected to expand the growth scope for the global atopic dermatitis market size. An increase in number of patients suffering from various skin disorders, changes in climatic conditions, and the rise in disposable income in both developed and developing countries are further expected to accelerate the growth of atopic dermatitis market analysis. Besides, the emergence of the latest technologies in the medical sector and the introduction of innovative procedures are magnifying the atopic dermatitis market trends.

However, stringent regulations and generic competition restrict the growth of the market. Moreover, lack of competent individuals in hospitals and clinics, and changes in the economic strategy have a negative impact on the dermatitis atopica market.

The atopic dermatitis market share is segmented on the basis of drug class, route of administration, distribution channel, and region. By drug class, it is categorized into corticosteroids, calcineurin inhibitors, PDE4 inhibitors, biologics, and others. Depending on indication, it is classified into topical, injectable, and oral. According to end user, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲 https://www.alliedmarketresearch.com/purchase-enquiry/3353

By route of administration, the injectable segment generated the highest revenue in the atopic dermatitis market in 2021, owing to product approvals of drugs such as dupilumab.

By distribution channel, the hospital pharmacies segment generated the highest revenue in the atopic dermatitis market in 2021, owing to high prevalence of dermatitis, rise in prices of drugs, increase in income levels of poor & middle-class families, and approval of drugs.Moreover, discounts on repeated purchases, growing number of inititatives from various governmental bodies in improving the infrastructure of hospitals and pharmacies are expected to expand the growth scop of the hospital pharmacies segment. Additionally, easy availability of therapeutic drugs, affordability and convenience are some of the factors boosting the growth of the segment.

By region, North America accounted for the largest market share in the atopic dermatitis market in 2021 and is expected to retain its dominance throughout the atopic dermatitis market forecast period. This is primarily attributed to increase in prevalence of atopic dermatitis, increase in number of atopic dermatitis industry and rise in treatment awareness among the patient population. Moreover, well-established healthcare infrastructure, and early adoption of novel medications are expected to propel the growth of the market. For instance, as per the 2022 National Eczema Association, an estimated 16.5 million U.S. adults (7.3%) have atopic dermatitis that initially began at more than two years of age, with nearly 40% affected by moderate or severe disease.

𝐊𝐄𝐘 𝐅𝐈𝐍𝐃𝐈𝐍𝐆𝐒 𝐎𝐅 𝐓𝐇𝐄 𝐒𝐓𝐔𝐃𝐘

On the basis of drug class, the biologics segment held 81.47% share in the global market in 2021.

On the basis of route of administration, the injectable segment held the largest market share in 2021, and is expected to remain dominant throughout the forecast period.

On the basis of distribution channel, the hospital pharmacies segment held the largest market share in 2021, and is expected to remain dominant throughout the forecast period.

Region wise, North America is expected to experience the highest market share during the forecast period. This was attributed to increasing prevalence of atopic dermatitis, high treatment awareness among the patient population.

Contact:

David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.